Related Experiment Video
Updated: Dec 29, 2025
08:47
Oral Health Assessment by Lay Personnel for Older Adults
Published on: February 2, 2020
13.4K
Health Literacy in Individuals at Risk for Alzheimer's Dementia: A Systematic Review.
A Rostamzadeh1, J Stapels, A Genske
1Ayda Rostamzadeh, MD, Department of Psychiatry and Psychotherapy, University of Cologne, Kerpener Straße 62, 50937 Cologne, Germany, Phone: +49 (0)221 - 478 3870, Fax: +49 (0)221 - 478 6030,
The Journal of Prevention of Alzheimer'S Disease
|February 4, 2020
Summary
Health literacy (HL) is crucial for individuals at risk of Alzheimer's disease (AD) to understand complex health information. Research shows variable understanding and a need for better communication strategies to support informed decision-making.
Area of Science:
- Neuroscience
- Public Health
- Cognitive Science
Background:
- Health literacy (HL) is essential for navigating complex health information, particularly with advancements in early Alzheimer's disease (AD) detection and personalized prevention.
- Individuals at risk for AD face increasingly sophisticated data, necessitating robust HL skills to comprehend disease progression, risk factors, and potential interventions.
Purpose of the Study:
- To systematically review and summarize current research findings on health literacy (HL) within populations at risk for Alzheimer's disease (AD).
- To identify the state of evidence regarding how individuals at risk for AD access, understand, appraise, and apply health information.
Main Methods:
- A systematic review was conducted across major databases (PubMed, Cochrane Library, PsycINFO, Web of Science) using search terms related to HL, AD, amyloid, and risk.
- Eligible studies included those employing validated HL assessment tools and addressing dimensions of HL (access, understanding, appraisal, application) in at-risk individuals for Alzheimer's dementia.
Main Results:
- Twenty-six quantitative and nine qualitative studies were included, revealing a desire among at-risk individuals to gain knowledge about their brain health and dementia risk.
- Disclosure of risk can lead to psychological distress and altered benefit-risk perceptions, potentially influencing lifestyle choices and future planning.
- Understanding and appraisal of AD risk information are variable, influenced by multiple factors, with basic HL skills potentially impaired in mild cognitive impairment (MCI) due to cognitive decline.
Conclusions:
- Systematic assessment of HL in AD at-risk populations is currently limited, highlighting a significant gap in research.
- Effective communication tailored to individual needs and preferences is paramount when engaging with individuals at risk for AD.
- Substantial future research is required to comprehensively address HL in the context of Alzheimer's disease risk and prevention.
Keywords:
Alzheimer’s diseaseHealth literacyaccessdecision making in healthindividuals at riskmild cognitive impairmentunderstanding and evaluating health informationMore Related Videos
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
7.8K
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.5K
Related Concept Videos
01:21Health Literacy
5.1K
Health literacy is an individual's or a community's capacity to comprehend, receive, read, and use relevant healthcare information and services. The World Health Organization (WHO, 2018) defines health literacy as the cognitive and social skills that determine the ability of individuals to gain access to, understand, and use information in ways that promote and maintain good health. As a result, the WHO helps individuals manage long-term health concerns, participate in preventative...
5.1K
01:26Alzheimer's Disease: Overview
1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
01:26Atherosclerosis III: Management
279
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
279
01:30Dementia
458
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
458
01:22Alzheimer's Disease: Treatment
702
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
702
01:29Documentation in Long-Term and Home Healthcare Setting
1.4K
Documentation in long-term care facilities and home healthcare settings is crucial for ensuring continuous, coordinated, and comprehensive care for patients. Each setting has its specific documentation processes and tools:
Long-Term Care Facilities
Long-Term Care Facilities
1.4K